and , /PRNewswire/ -- Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that the Company will be presenting a corporate overview at the following investor conferences in September:

, /PRNewswire/ -- Although various market revenue projections may differ in the total dollar figures, the reports in the triple negative breast cancer (TNBC) treatment market all predict a sustainable...

and , /PRNewswire/ --  Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC) today announced the first patient has been dosed in the Company's investigator-sponsored phase 2 study of pelareorep-anti-PD-1...

, /PRNewswire/ --   – In the fight against some of the most challenging forms of cancer, (NYSE:AZN) recently placed a giant  on an antibody-drug conjugate (ADC) called DS-1062 from Japanese developers...

In the fight against some of the most challenging forms of cancer, AstraZeneca PLC (NYSE:AZN) recently ...

and , /PRNewswire/ -- Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that the Company will participate in a virtual fireside chat at the Canaccord Genuity 40 Annual Growth Conference....

and , /PRNewswire/ -- Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC) today announced its financial results and operational highlights for the quarter ended . All dollar amounts are expressed in Canadian...

, /PRNewswire/ --   – In a major step forward, engineers from have designed nanoparticles that stimulate the immune system, helping it to attack tumors. This could contribute significantly to other...

, /PRNewswire/ -- The triple negative breast cancer (TNBC) treatment market to grow at stellar CAGR through 2026. A  from Cole Market Research has stated that the ongoing advancements in cancer research...

and , /PRNewswire/ --

, /PRNewswire/ -- Metastatic breast cancer (also called stage IV) is breast cancer that has spread to another part of the body, most commonly the liver, brain, bones, or lungs. Metastatic disease is NOT...

and , /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), today announced the first patient has been dosed in the Company's phase 2 study of pelareorep-based combination therapies in...

and , /PRNewswire/ -- Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced that it has entered into...

and , /PRNewswire/ -- Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), today provided a recap of a Key Opinion Leader (KOL) call sponsored by Canaccord Genuity and held on . The call focused on recently...

and , /PRNewswire/ -- Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced the publication of an electronic-poster...

and , /PRNewswire/ -- Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced the publication of an electronic-poster...

and , /PRNewswire/ --  Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced the publication of two abstracts in...

and , /PRNewswire/ -- Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced that , President & CEO of...

and , /PRNewswire/ --  Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced its financial results and...

and , /PRNewswire/ -- Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced the the voting results from...